Remove Data Remove Epilepsy Remove Patients Remove Safety
article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Patients who suffer from epilepsy , which affects some 3.4 This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8

article thumbnail

Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

Cannabis Law Report

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Systematic review and meta-analysis were performed to examine the efficacy and safety of MCs treatment among children.

Safety 52
article thumbnail

Sapphire Medical Clinics expands patient access to cheapest medical cannabis fees in UK

Cannabis Law Report

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

article thumbnail

Answer of the Day for Jul 18, 2022

TheAnswerPage

In 2017, researchers performed an analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Two thirds of patients reported improvement in the frequency of seizures (399/622, 64%). Are CBD-rich extracts more effective at reducing seizures compared to purified CBD products?

article thumbnail

France seeks patients for medicinal cannabis trial

Cannabis Law Report

France is searching for patients to take part in an official medical cannabis trial, but users will not be smoking the drug. The two-year experiment is being overseen by the French Agency for Drug Safety (ANSM), which drew up a 13-name committee to explore the possibilities of reform in one of Europe’s largest markets in December 2018.